Elenestinib
From Wikipedia, the free encyclopedia
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | BLU-263 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H29FN10O |
| Molar mass | 528.596g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Elenestinib is an investigational new drug that is being evaluated by Blueprint Medicines (a Sanofi company) for the treatment of indolent and smoldering systemic mastocytosis (SM), a rare disease where excess abnormal mast cells build up in internal organs, causing allergy‐like symptoms and organ damage. It is an inhibitor of the proto-oncogene c-kit protein harboring the D816V SM driver mutation.[1] [2]
Clinical trials
[edit ]Elenestinib is in phase 3 clinical trials for systemic mastocytosis.[3]
References
[edit ]- ↑ "Elenestinib - Blueprint Medicines". AdisInsight. Springer Nature Switzerland AG.
- ↑ Valent P, Hartmann K, Stefanzl G, Filik Y, Bauer K, Degenfeld-Schonburg L, et al. (February 2026). "Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation". Current Allergy and Asthma Reports. 26 (1) 10. doi:10.1007/s11882-026-01257-6. PMC 12913350 . PMID 41701410.
- ↑ Clinical trial number NCT04910685 for "(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis" at ClinicalTrials.gov
Stub icon
This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.